Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimeric naphthoquinone 1 is a naturally-derived small molecule compound isolated from Diospyros lotus and other plant sources, characterized structurally as 5,4′-dihydroxy-1′-methoxy-6,6′-dimethyl-7,3′-binaphthyl-1,4,5′,8′-tetraone. It represents a rare class of binaphthyl-linked naphthoquinones with demonstrated antiproliferative effects, notably by acting on multidrug resistance (MDR) efflux pumps in cells and showing moderate antagonism in combination index analysis for MDR modulation[2]. Mechanistically, dimeric naphthoquinones including this compound act through redox cycling, inhibition, and interaction with NAD(P)H dehydrogenase, quinone 1 (NQO1), leading to excessive production of reactive oxygen species (ROS), disruption of cellular oxidative balance, and mitochondrial dysfunction[1][3][6]. Its cytotoxicity has been most researched in highly proliferative cells such as leukemia, breast, and prostate cancer cell lines, with effects stemming from the induction of oxidative stress and selective targeting of NQO1 as a major cellular target[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimeric naphthoquinone 1.